Pleomorphic liposarcoma: clinical observations and molecular variables.

Area of Science:

• Oncology
• Surgical Pathology
• Molecular Diagnostics

Background:

• Pleomorphic liposarcoma (PLS) is a rare, high-grade sarcoma characterized by lipoblastic differentiation.
• Understanding the natural history and patient outcomes of PLS is essential for improving management.
• Identifying key protein biomarkers associated with PLS progression is a critical research area.

Purpose of the Study:

• To evaluate the natural history and patient outcomes of pleomorphic liposarcoma.
• To identify independent prognostic factors for PLS.
• To analyze commonly deregulated protein biomarkers and p53 gene mutations in PLS.

Main Methods:

• Retrospective review of medical records for 155 PLS patients (1993-2010).
• Univariate and multivariate analyses to determine prognosticators.
• Tissue microarray construction (n=56) for immunohistochemical analysis and p53 gene sequencing (exons 5-9).

Main Results:

• The 5-year disease-specific survival rate was 53%.
• Recurrent disease, unresectability, and positive margins were poor prognostic indicators; systemic relapse was the strongest predictor.
• Increased expression of adipogenic, survival, and angiogenic markers was observed, along with frequent loss of retinoblastoma protein and high p53 mutation rates (~60%).

Conclusions:

• Pleomorphic liposarcoma is an aggressive sarcoma with a high propensity for metastasis.
• Identifying common molecular events driving PLS progression is vital for advancing patient care and improving outcomes.